Ribo Life Science(06938.HK): Milestone Achieved with Selection of First Candidate Drug under Collaboration with Madrigal
NewTimeSpace News: On July 2, 2026, Ribo Life Science(06938.HK) released a voluntary announcement, stating that the Company and Madrigal Pharmaceuticals have hit the candidate selection milestone for their first asset within their siRNA collaboration project, and will immediately initiate investigational new drug (IND)-enabling studies.
The two parties entered into an exclusive global licensing agreement covering multiple siRNA assets on 11 February 2026. The cooperation intends to leverage the Company’s validated liver-targeted RiboGalSTARTM platform to develop RNA therapeutics for liver diseases, with a primary focus on metabolic dysfunction-associated steatohepatitis (MASH).
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Ribo Life Science(06938.HK): Proposed Acquisition of 25.93% Equity Stake in Xingborun for RMB 70 Million
- Riborn Bio-B (06938.HK): Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism
- Raybow Biotech - B (6938.HK): Achieves Third Key Milestone in MASH R&D Collaboration with Boehringer Ingelheim
